Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI

Core Insights - Hemostemix Inc. is hosting a webinar focused on its autologous stem cell therapy, ACP-01, aimed at vascular surgeons in Florida, particularly for patients suffering from chronic limb-threatening ischemia (CLTI) who have no revascularization options [1][3][4] Company Overview - Hemostemix is a leader in autologous stem cell therapy, offering VesCell™ (ACP-01) for various conditions including angina, peripheral arterial disease, and chronic limb-threatening ischemia [1][8] - The company has completed seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed journals [8] - ACP-01 has shown promising clinical outcomes, including a 0% mortality rate and an 83% wound healing rate in patients followed for up to 4.5 years [8] Webinar Details - The webinar is scheduled for October 29, 2025, and will provide Florida-based practitioners with clinical knowledge and operational tools to implement ACP-01 therapy [3][5] - Attendees will receive resources such as patient screening tools and compliance checklists specific to Florida regulations [5][7] Clinical Context - Amputation rates among no-option CLTI patients are high, with 12,059 cases reported in 2023, highlighting the need for effective alternatives like ACP-01 [2] - ACP-01 is designed to stimulate angiogenesis and promote natural tissue healing using the patient's own blood-derived cells, offering a minimally invasive treatment option [2][7]